Outsourcing

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

Complex and potent molecules demand greater technical and regulatory expertise to ensure safe handling.


In Safe Hands

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Pharmaceutical Technology spoke with Anil Kane, executive director, global science and technology, pharmaceutical development services, at Thermo Fisher Scientific about the industry’s need for more capacity in the manufacture of highly potent APIs.

Ensuring Manufacturing of HPAPIs Under Safe Conditions

Susan Haigney is lead editor of Pharmaceutical Technology and Pharmaceutical Technology Europe.

Does the pharmaceutical industry have adequate access to contained equipment, facilities, and infrastructure for the manufacture of highly potent APIs?

HPAPI Capacity Challenges

Jiawei Chen, PhD, is global strategic marketing manager at SCIEX.

Key considerations when searching for an analytical service provider include workflow, hardware, and regulatory support.

Best Practices for Selecting a Service Provider

Catalent Biologics has entered into a long-term strategic agreement to develop and manufacture an AveXis gene therapy treatment for spinal muscular atrophy (SMA), Zolgensma. 

Catalent Biologics Announces Long-Term Strategic Agreement to Develop Zolgensma

Catalent recently held a groundbreaking ceremony at its Bloomington, Indiana pharmaceutical fill/finish site. 

Catalent Breaks Ground at $112-Million Drug Product Manufacturing Facility

The expansion of Lonza’s Tampa site includes development and manufacturing capabilities for oral solid-dose drugs.

Lonza Expands Florida Solid-Dose Facility

Metabolic-disease biotech Amicus Therapeutics announced a manufacturing agreement with Catalent’s Paragon Gene Therapy unit for gene therapy manufacturing.

Amicus Partners with Catalent on Lysosomal Disease Gene Therapy Programs

Amicus Therapeutics has entered into a strategic gene therapy development and manufacturing collaboration with Brammer Bio, which is a part of Thermo Fisher Scientific.

Amicus Therapeutics Enters Strategic Manufacturing Collaboration with Thermo

The increasing growth in the cell- and gene-therapy markets is inspiring CDMOs to expand their services in this emerging biologic drug arena. 

Contract Manufacturing Services